Abstract
(Abstracted from Ultrasound Obstet Gynecol 2022;59:33–39) First described in 1997, the presence of cell-free fetal DNA in maternal plasma has been increasingly used in the last decade for cell-free DNA (cfDNA)–based noninvasive prenatal testing (NIPT) thanks to advances in molecular genetic technology. This method, now commonly used in the detection of fetal chromosomal abnormalities, can test for a variety of conditions.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
